Inclusion Criteria:

   - Subjects must have histologically or cytologically confirmed primary invasive breast
   cancer, ductal carcinoma in situ (DCIS) or primary invasive breast cancer with a DCIS
   component.

   - Female, age of 18 years or older.

   - Subjects must have received neoadjuvant therapy for this breast cancer diagnosis prior
   to their lumpectomy procedure (cohorts 1 and 2).

   - Subjects must be scheduled for a lumpectomy for a breast malignancy.

   - Subjects must be able and willing to follow study procedures and instructions.

   - Subjects must have received and signed an informed consent form.

   - Subjects must have no uncontrolled serious medical problems except for the diagnosis
   of cancer, as per the exclusion criteria listed below.

      - Leukocytes > 1,000/mcL

      - Platelets > 50,000/mcL

      - total bilirubin within normal institutional limits

      - AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal

      - eGFR >= 60mL/min/1.73m2

   - Subjects with ECOG performance status of 0 or 1.

Exclusion Criteria:

   - Subjects who have been diagnosed with bilateral breast cancer and are undergoing
   bilateral resection procedure.

   - Subjects who are pregnant at the time of diagnosis of their breast cancer.
   Breastfeeding should be discontinued if the mother is treated with LUM015.

   - Subjects who are sexually active and not willing/able to use medically acceptable
   forms of contraception (hormonal or barrier method of birth control, abstinence) upon
   entering the study and for 60 days after injection of LUM015.

   - Subjects who have taken an investigational drug within 14 days of enrollment.

   - Subjects who will have administration of methylene blue or any blue or green dye for
   sentinel lymph node mapping on the day of the surgery prior to imaging the lumpectomy
   cavity with the LUM Imaging Device.

   - Subjects who have not recovered from adverse events due to other pharmaceutical or
   diagnostic agents.

   - Subjects with uncontrolled hypertension defined as persistent systolic blood pressure
   > 180 mm Hg, or diastolic blood pressure > 110 mm Hg; those subjects with known HTN
   should be stable within these ranges while under pharmaceutical therapy.

   - Subjects with a history of allergic reaction to polyethylene glycol (PEG).

   - Subjects with a history of allergic reaction to any oral or intravenous contrast
   agents.

   - Uncontrolled intercurrent illness including, but not limited to ongoing or active
   infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
   arrhythmia, COPD or asthma requiring hospitalization within the past 12 months, or
   psychiatric illness/social situations that would limit compliance with study
   requirements.

   - HIV-positive individuals on combination antiretroviral therapy are ineligible because
   of the potential for pharmacokinetic interactions with LUM015.

   - Any subject for whom the investigator feels participation is not in the best interest
   of the subject.

   - Subjects undergoing a second lumpectomy procedure because of positive margins in a
   previous surgery prior to entering this study.

   - Subjects with prior ipsilateral breast cancer surgeries, mastectomies, breast
   reconstructions or implants.

   - Subjects who have undergone a surgical biopsy for any reason in the ipsilateral breast
   performed less than 2 years prior to enrollment of this study.

   - Subjects with prior ipsilateral reduction mammoplasties (breast reductions) performed
   less than 2 years prior to enrollment to this study.

   - Subjects undergoing breast conserving surgery whose resected specimen (main lump,
   shaves, or any other resected tissue) will be evaluated with frozen section after the
   Lumicell-guided removal of shaves.

   - Subjects with a history of allergic reaction to Tegaderm